Clinical Trial Update: Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial of TJ003234 (anti-GM-CSF monoclonal antibody) in severe COVID-19 completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease 2019

Drugs mentioned

• TJ003234 (anti-GM-CSF monoclonal antibody)

Snippet

Sponsor: I-Mab Biopharma US Limited | Conditions: Coronavirus Disease 2019 COVID-19 | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-05-06